Figures
- FIGURE 1.
Reduction in craving expressed as area under the curve during 60 min for a) Nicorette 4 mg gum (♦), mouth spray (▴), lozenge (•) and placebo lozenge (▪); and b) Nicorette 4 mg gum (⋄), pouch (▵) and placebo pouch (□) [20]. VAS: visual analogue scale.
- FIGURE 2.
Mean subjective ratings of product preference (n = 47). ░: NicoNovum mouth spray; ▪: NicoNovum lozenge; ▒: Nicorette gum; □: placebo lozenge. *: p<0.05.
- FIGURE 3.
Mean subjective ratings of product preference (n = 30). ░: NicoNovum pouch; ▒: Nicorette gum; □: placebo pouch. *: p<0.05.
- FIGURE 4.
Continuous smoking cessation rate (%) between week 9 and 52 in two studies [32, 34]. ░: varenicline (n = 343 and n = 349 for the studies by Jorenby et al. [32] and Gonzales et al. [34], respectively); ▒: buproprion (n = 340 and n = 329, respectively); □: placebo (n = 340 and n = 344, respectively).
